Literature DB >> 12127679

Alteration of midkine expression in the ischemic brain of humans.

Manabu Wada1, Makiko Kamata, Yoshinori Aizu, Takashi Morita, Jianguo Hu, Kiyomitsu Oyanagi.   

Abstract

Midkine (MK) is a heparin-binding growth factor that occurs as a product of the retinoic acid-inducible gene. Alteration of MK expression in ischemic brain lesions was examined in humans immunohistochemically in nine patients and in two control subjects without neurological disorders. Some neurons were MK-immunopositive, but no evident MK-immunoreactivity was observed in astrocytes in brains of control subjects. In the ischemic lesions, significant elevation of MK-immunoreactivity in the astrocytes and depletion of the reactivity in neurons were seen, especially in the early period, where edema and eosinophilic neurons were prominent. On the other hand, MK-immunoreactivity was not observed in hypertrophic and fibrillary astrocytes in the later period. These findings suggest that the MK in astrocytes play some role in the repair process in the early period of the ischemic brain lesions in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127679     DOI: 10.1016/s0022-510x(02)00134-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Ethanol activates midkine and anaplastic lymphoma kinase signaling in neuroblastoma cells and in the brain.

Authors:  Donghong He; Hu Chen; Hisako Muramatsu; Amy W Lasek
Journal:  J Neurochem       Date:  2015-08-11       Impact factor: 5.372

2.  Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas.

Authors:  S Ikematsu; A Nakagawara; Y Nakamura; S Sakuma; K Wakai; T Muramatsu; K Kadomatsu
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

Review 3.  Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury.

Authors:  Emily Ross-Munro; Faith Kwa; Jenny Kreiner; Madhavi Khore; Suzanne L Miller; Mary Tolcos; Bobbi Fleiss; David W Walker
Journal:  Front Neurol       Date:  2020-10-22       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.